abstract: UNASSIGNED: Delayed @entity9991 (DHTR) are potentially life-threatening complications in @entity1 with @entity3458 ( @entity3458 ). Between 1 August 2008 and 31 December 2013, 220 of 637 adult @entity1 in our centre had at least one red blood cell (RBC) transfusion in 2158 separate transfusion episodes. Twenty-three DHTR events occurred in 17 @entity1 (13 female) including 15 HbSS, one HbSC and one HbSb(0) thalassaemia, equating to a DHTR rate of 7  7% of @entity1 transfused. Mean interval from RBC transfusion to DHTR event was 10  1      5  4  d, and typical presenting features were @entity221 , @entity158 and haemoglobinuria. Twenty of the 23 (87  0%) DHTR episodes occurred following transfusion in the acute setting. Notably, 11/23 (47  8%) of DHTRs were not diagnosed at the time of the event, most were misdiagnosed as a @entity432 . 16/23 DHTRs had 'relative reticulocytopenia', which was more common in older @entity1 . Seven of 23 episodes resulted in alloantibody formation, and three caused autoantibody formation. DHTRs are a severe but uncommon complication of RBC transfusion in @entity3458 and remain poorly recognized, possibly because they mimic an acute @entity158 crisis. Most of the DHTRs are triggered by RBC transfusion in the acute setting when @entity1 are in an inflammatory state.

title: Delayed XXXX in adults with @entity3458 : a 5-year experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['SCD', 'sickle cell disease']

entities_list: @entity9991 :: ('MESH:D065227', 'Disease') :: ['haemolytic transfusion reactions']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'painful']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['vaso-occlusive crisis']

answer: @entity9991 :: (MESH:D065227,Disease) :: ['haemolytic transfusion reaction']


abstract: Nine @entity3494 (As)-resistant bacterial strains isolated from As-rich groundwater samples of West Bengal were characterized to elucidate their potential in geomicrobial transformation and bioremediation aspects. The 16S rRNA gene-based phylogenetic analysis revealed that the strains were affiliated with genera Actinobacteria, Microbacterium, Pseudomonas and Rhizobium. The strains exhibited high resistance to As [Minimum inhibitory concentration (MIC) >=  10  mM @entity13303 and MIC >=  450  mM @entity24809 ] and other heavy metals, e.g., @entity8863 , @entity3412 , @entity3411 , etc. (MIC >=  2  mM) as well as As transformation ( @entity13303 oxidation and @entity24809 reduction) capabilities. Their ability to utilize diverse @entity505 source(s) including @entity9436 and different alternative electron acceptor(s) ( @entity24809 , @entity597 , @entity17464 , etc.) during anaerobic growth was noted. Growth at wide range of pH, temperature and salinity, production of siderophore and biofilm were observed. Together with these, growth pattern and transformation kinetics indicated a high @entity13303 oxidation activity of the isolates Rhizobium sp. CAS934i, Microbacterium sp. CAS905i and Pseudomonas sp. CAS912i. A positive relation between high @entity13303 resistance and @entity13303 oxidation and the supportive role of @entity13303 in bacterial growth was noted. The results highlighted @entity13303 oxidation process and metabolic repertory of strains indigenous to contaminated groundwater and indicates their potential in @entity13303 detoxification. Thus, such metabolically well equipped bacterial strains with highest @entity13303 oxidation activities may be used for bioremediation of As contaminated water and effluents in the near future.

title: Characterization of arsenite-oxidizing bacteria isolated from XXXX -contaminated groundwater of West Bengal.

entities_list: @entity9436 :: ('MESH:D006838', 'Chemical') :: ['hydrocarbons']

answer: @entity3494 :: (MESH:D001151,Chemical) :: ['arsenic']


abstract: UNASSIGNED: 367 Background: @entity6219 is an multi- @entity4149 kinase inhibitor shown to prolong progression-free survival (PFS) compared to placebo in treatment-naive and cytokine-refractory @entity1358 . Outcomes and safety on its use after TT are limited. METHODS: We retrospectively reviewed records of consecutive pts with @entity1358 who were treated with @entity6219 between November 2009-November 2011 after having @entity74 ( @entity74 ) with other TT. Radiographic response was assessed by a blinded radiologist using RECIST v1.1 criteria. PFS and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. Hazard ratios (HR) were estimated by fitting univariable and multivariable Cox proportional hazards models to evaluate the association of PFS with @entity1 co-variates. RESULTS: 112 pts (median age 63 years, 67% male, 83% clear cell) met inclusion criteria. Median number of previous TT was 2 (range 1-5). 85 events ( @entity74 or @entity204 ) occurred. 14 pts (12.5%) had a partial response. Median PFS was 5.7 months (95% CI: 4.3-8.9 months). PFS was significantly associated with male gender (HR=0.55; 95% CI: 0.34-0.87; p=0.011), clear-cell histology (HR=0.42; 95% CI: 0.24-0.74; p=0.0031), number of metastatic sites (HR= 1.26; 95% CI: 1.05-1.52; p=0.0123), pancreatic @entity3 (HR=0.40; 95% CI: 0.18-0.85;p=0.0185), Karnofsky PS< 80 (HR=2.07; 95% CI: 1.22-3.48; p=0.0062), and elevated LDH (HR=1.63; 95% CI: 1.03-2.573; p=0.035). Median @entity1349 was 16.9 months (95% CI: 10.3-21.9). 26% of pts were still receiving @entity6219 at the time of analysis. 51% discontinued @entity6219 due to @entity74 and 12% died of @entity74 on treatment. 11% discontinued @entity6219 due to adverse events (AEs). There were no treatment related @entity204 . Common AEs included @entity1295 (43%), increase LFTs (34%), @entity294 (28%), @entity390 / @entity391 (14%), @entity448 (14%), @entity101 exacerbation (12%), and @entity1375 (11%). 89% of AEs were grade 1/2. CONCLUSIONS: @entity6219 demonstrated meaningful clinical activity in heavily pretreated pts with @entity1358 following @entity74 with other TT. AEs were mild/moderate and manageable.

title: Outcomes of @entity1 (pts) with XXXX ( @entity1358 ) treated with @entity6219 after progression on other targeted therapies (TT): Updated results.

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism']

entities_list: @entity6219 :: ('MESH:C516667', 'Chemical') :: ['pazopanib', 'Pazopanib']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['metastatic renal cell carcinoma']


abstract: PURPOSE: To assess the add-on efficacy of @entity4677 on the EEG, behavior, and cognition of @entity1 with @entity25 ( @entity25 ). METHODS: Charts of @entity1 with behavioral and/or @entity73 associated with @entity25 who received @entity4677 at 50 mg/kg/day as add-on treatment were retrospectively reviewed. Awake and sleep EEG recordings and detailed neuropsychological and behavioral assessments were available at baseline and 2 months after @entity4677 initiation. In @entity1 showing clinical and/or electrophysiological improvement after 2 months, @entity4677 was continued with a new evaluation at 1 year. RESULTS: Twelve @entity1 were included (9 cryptogenic and 3 symptomatic cases). Seven @entity1 (58.3%) showed improvement of EEG record. Among these seven @entity1 , neuropsychological evaluation was improved in three, and in the other four @entity1 , not testable because of severe @entity73 , behavior was improved. Two @entity1 improved in neuropsychological evaluation despite the lack of EEG improvement. Eight @entity1 (66.6%) continued @entity4677 treatment after 2 months. After 1 year, four @entity1 were still on @entity4677 , two because sustained effect on EEG and behavior and the two others because improvement in neuropsychological testing despite unchanged EEG. @entity4677 was discontinued in the other four @entity1 because of neuropsychological or behavioral deterioration associated with @entity25 pattern, between 9 and 11 months after treatment initiation. CONCLUSIONS: This retrospective study suggests that @entity4677 has a positive effect on the EEG, the behavior, and the cognition of @entity1 with @entity302 and @entity25 . Additional studies are warranted in order to assess the place of this drug in these @entity302 conditions.

title: @entity4677 efficacy in XXXX with @entity25 : experience in 12 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity4677 :: ('MESH:C026098', 'Chemical') :: ['levetiracetam', 'Levetiracetam']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'cognitive deterioration']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic', 'epilepsy']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['continuous spikes and waves during slow sleep', 'CSWS']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epileptic syndromes']


abstract: Contrasting the wealth of information that is available about various biological and therapeutic aspects of @entity1 @entity2280 + stem cells, little data exist concerning their quantity and dynamics as well as their mutual relationships with other hematopoietic constituents in the bone marrow of @entity1 with @entity102 . In comparison with a control group frequency of progenitors is significantly increased in @entity1860 ( @entity1860 ). Following different therapeutic modalities their quantity reflects therapeutic efficacy (responder and non-responder @entity1 ) and therefore exerts a predictive value regarding acceleration and blastic crisis. The significant correlations between fiber content and number of these precursors elucidates the complex interactions between stroma and progenitor cell differentiation and maturation. Following allogeneic bone marrow transplantation there is a rapid recovery of the @entity2280 + stem cell population in the first month. A higher number of these cells is related with graft size, an earlier independence for platelet transfusion and a more extended regeneration of erythro- and megakaryopoiesis. The slight increase in reticulin fibers in these @entity1 may be associated with the complex and so far ill-defined pathomechanism of homing (adherence to the fibrous matrix). In @entity4018 ( @entity4018 ) an increased number of @entity2280 + stem cells is found predominantly in the early (prefibrotic or mild fibrotic) hypercellular stages and probably indicates a higher proliferative activity of the precursor cell pool. According to sequential biopsies most @entity1 with early @entity4018 that later evolved into an overt fibrosclerotic stage usually display a reduction of progenitor cells during the development of @entity4018 . The unequal distribution of @entity2280 + stem cells in the bone marrow versus spleen in @entity4018 (advanced fibrosclerotic stage) is in support of the currently discussed hypothesis of splenic filtration and concentration of precursor cells as an essential feature of @entity4018 . Regarding prognosis in @entity1860 a higher amount of @entity2280 + stem cells is significantly associated with an unfavorable survival and thus confirms the assumed implication of an accelerated phase of disease at onset. On the other hand, in @entity6582 vera (PV) and @entity4018 a low number of progenitors is probably due to a decreased proliferation rate (reduced hematopoietic turnover index) and therefore reflects a reduction in the regenerative capacity of @entity1210 . For this reason, a presumptive defect in the recovery of normal and clonally transformed stem cells is speculated to add to the worsening of prognosis by causing the well-known @entity236 in terminal stage PV and @entity4018 .

title: XXXX + stem cells in @entity102 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity6582 :: ('MESH:D011086', 'Disease') :: ['polycythemia']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic myeloproliferative disorders']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow insufficiency']

entities_list: @entity4018 :: ('MESH:D055728', 'Disease') :: ['idiopathic myelofibrosis', 'myeloid metaplasia', 'myelofibrosis', 'IMF']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia']

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['hematopoiesis']

answer: @entity2280 :: (947,Gene) :: ['CD34']


abstract: OBJECTIVE: We investigated the anti-inflammatory activity of @entity176 (SR) in @entity625 models. MATERIALS AND METHODS: @entity35 received 1 mg zymosan (Zy) or saline intra-articularly. Other groups were subjected to anterior cruciate ligament transection in the right knee, as an @entity571 ( @entity571 ) model, or a sham procedure. Joint @entity158 was assessed using the articular incapacitation and paw-pressure tests. Cell influx and cytokines were measured in joint exudates. TREATMENT: Groups received either SR (30-300 mg/kg per os) or saline. RESULTS: SR dose-dependently and significantly inhibited @entity158 in both Zy and @entity571 models, while not altering cell influx. @entity1510 administration significantly reversed SR @entity1337 . SR significantly reduced levels of @entity3426 and @entity5 @entity39 factor-a in @entity625 , whereas those of @entity4646 were not altered. CONCLUSIONS: SR provides @entity1337 in @entity625 that is associated to inhibition of the release of inflammatory cytokines into inflamed joints. This effect is abrogated by administration of the opioid antagonist @entity1510 .

title: @entity176 @entity1337 in XXXX models is associated to decreased cytokine release and opioid-dependent mechanisms.

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['Zy arthritis', 'arthritis']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis', 'OA']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['Naloxone', 'naloxone']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['joint pain', 'pain']

entities_list: @entity176 :: ('MESH:C081587', 'Chemical') :: ['strontium ranelate']

entities_list: @entity4646 :: ('81503(Tax:10116)', 'Gene') :: ['cytokine-induced neutrophil chemoattractant (CINC)-1']

answer: @entity625 :: (MESH:D001168,Disease) :: ['arthritis']


abstract: Despite recognition that cholinesterase inhibitors can provide clinical benefits for @entity1 with @entity195 ( @entity195 ), the average durations of treatment and beneficial effects are not optimal in all cases. This may be due to disappointing efficacy or poor tolerability of the initial treatment, as well as secondary efficacy failure or adverse effects emerging during the maintenance phase. In such cases, pharmacological differences between available cholinesterase inhibitors provide a good rationale to switch to another drug in the same class. The pharmacological properties of @entity11544 , a dual inhibitor of @entity10810 ( @entity10810 ) and butyrylcholinesterase, and @entity8124 and @entity11545 , two @entity10810 -selective inhibitors, are reviewed. @entity11544 is reported to show brain- and brain region-selectivity. @entity8124 appeared to be more selective for central than peripheral enzymes in @entity35 . @entity11545 and @entity8124 have also been shown to exert nicotinic receptor allosteric modulation in vitro, while @entity11544 has been shown to increase binding of @entity934 to nicotinic receptors in the @entity195 brain. @entity8124 and @entity11545 are metabolised by the hepatic CYP450 system, whereas @entity11544 is metabolised by its target enzymes. Several switching studies indicated that a substantial proportion of @entity1 who fail to benefit from treatment with @entity8124 could draw benefits after being switched to @entity11544 . An immediate switch from @entity8124 to @entity11544 was reported to be well tolerated and was not associated with cholinergic side effects. A post hoc analysis of a 5-month trial with @entity11545 showed that @entity1 had similar efficacy outcomes, whether or not they had received prior anticholinesterase therapy, suggesting that a previous failure to respond to another cholinesterase inhibitor did not predict response to @entity11545 . On the basis of available data it is suggested that @entity1 not tolerating or not responding to one particular cholinesterase inhibitor may still draw benefits upon switching to another.

title: Switching cholinesterase inhibitors in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity11545 :: ('MESH:D005702', 'Chemical') :: ['galantamine', 'Galantamine']

entities_list: @entity11544 :: ('MESH:C072506', 'Chemical') :: ['Rivastigmine', 'rivastigmine']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity10810 :: ('43', 'Gene') :: ['AChE', 'acetylcholinesterase']

entities_list: @entity8124 :: ('MESH:C076946', 'Chemical') :: ['donepezil', 'Donepezil']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: @entity1457 protein 90-beta ( @entity31652 ) is associated with cell proliferation, differentiation and apoptosis and has been investigated as a prognostic factor in many @entity5 . However, @entity31652 protein expression in @entity2220 (ADC) has not been thoroughly elucidated. The aim of this study was to determine the relationship between @entity31652 expression, clinicopathological parameters and prognosis in @entity2220 . Seventy-five surgically resected @entity2220 and matched normal lung tissue samples were obtained to construct a @entity3145 ( @entity3145 ), including 44 stage IA-IB cases. Then, @entity31652 protein expression level in lung tissue was evaluated by immunohistochemistry. Kaplan-Meier survival analysis with a Log-rank significance test was used to estimate the survival differences among subgroups according to @entity31652 expression in lung ADC tissues using SigmaPlot/SigmaStat v10 and 3.5, respectively. @entity31652 protein expression was significantly upregulated in lung ADC tissues compared to that in the matched normal alveoli (P<0.001) and was associated with @entity5 differentiation (P<0.001). Furthermore, @entity31652 over-expression was correlated with poor survival in stage I @entity1 (P=0.026). Increased @entity31652 expression was associated with reduced overall survival (HR, 2.440; 95% confidence interval, 1.076-5.530; P=0.033). To conclude, our data demonstrated that @entity31652 protein was over-expressed in lung ADC @entity5 tissues and was associated with poor outcomes in early stage ADC @entity1 and low pathological @entity5 . These data suggest that @entity31652 could be a clinically useful biomarker for the prognosis of ADC and an effective anticancer target.

title: @entity1457 protein 90-b over-expression is associated with poor survival in stage I lung adenocarcinoma XXXX .

entities_list: @entity3145 :: ('MESH:D017695', 'Disease') :: ['tissue microarray', 'TMA']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'grade tumors', 'cancers']

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['Heat shock']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinomas', 'lung adenocarcinoma']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Relapsed or refractory diffuse large B-cell and @entity1073 have a poor prognosis. The EPOCH regimen and rituximab monotherapy have demonstrated activity as salvage therapies. Because of their non-overlapping @entity137 , we evaluated their combination as salvage therapy in a phase II study. @entity1 AND METHODS: @entity1 with relapsed or refractory @entity2225 -positive large B-cell and @entity1073 were offered treatment with rituximab 375 mg/m2 intravenously (i.v.) on day 1, @entity632 15 mg/m2 as a continuous i.v. infusion on days 2-4, @entity2879 65 mg/m2 as a continuous i.v. infusion on days 2-4, @entity1891 0.5 mg as a continuous i.v. infusion on days 2-4, @entity786 750 mg/m2 i.v. on day 5 and @entity229 60 mg/m2 orally on days 1-14. RESULTS: Fifty @entity1 , with a median age of 56 years (range 23-72), entered the study. Twenty-five had primary diffuse large @entity1892 , 18 transformed large @entity1892 and seven @entity1073 . The median number of prior chemotherapy regimens was 1.7 (range one to four). The median number of treatment cycles was four (range one to six). Possible treatment-related @entity204 occurred in two @entity1 . Objective responses were obtained in 68% of @entity1 (28% complete responses, 40% partial responses). Nineteen @entity1 received consolidating high-dose chemotherapy with autologous stem-cell transplantation. The median follow-up was 33 months. Three @entity1 developed a secondary @entity2590 . The median overall survival was 17.9 months; the projected overall survival at 1, 2 and 3 years was 66, 42 and 35%, respectively. The median event-free survival was 11.8 months; the projected event-free survival at 1, 2 and 3 years was 50, 30 and 26%, respectively. CONCLUSION: The rituximab-EPOCH regimen is effective and well tolerated, even in extensively pretreated @entity1 with relapsed or refractory large @entity1892 and @entity1073 .

title: Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed XXXX : results of a phase II study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma']

entities_list: @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle-cell lymphoma']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

answer: @entity1892 :: (MESH:D016393,Disease) :: ['B-cell lymphomas']


abstract: Importance: Oxidative stress and @entity455 are believed to partly mediate age-related @entity73 , a strong risk factor for development of @entity303 . Epidemiologic studies suggest that a Mediterranean diet, an antioxidant-rich cardioprotective dietary pattern, delays @entity73 , but clinical trial evidence is lacking. Objective: To investigate whether a Mediterranean diet supplemented with antioxidant-rich foods influences cognitive function compared with a control diet. Design, Setting, and @entity1 : Parallel-group randomized clinical trial of 447 cognitively healthy volunteers from Barcelona, Spain (233 @entity1 [52.1%]; mean age, 66.9 years), at high cardiovascular risk were enrolled into the Prevenci  n con Dieta Mediterr  nea nutrition intervention trial from October 1, 2003, through December 31, 2009. All @entity1 underwent neuropsychological assessment at inclusion and were offered retesting at the end of the study. Interventions: @entity1 were randomly assigned to a Mediterranean diet supplemented with extravirgin olive oil (1 L/wk), a Mediterranean diet supplemented with mixed nuts (30 g/d), or a control diet (advice to reduce dietary fat). Main Outcomes and Measures: Rates of @entity73 over time based on a neuropsychological test battery: Mini-Mental State Examination, Rey Auditory Verbal Learning Test (RAVLT), Animals Semantic Fluency, Digit Span subtest from the Wechsler Adult Intelligence Scale, Verbal Paired Associates from the Wechsler Memory Scale, and the Color @entity2205 Test. We used mean z scores of change in each test to construct 3 cognitive composites: memory, frontal (attention and executive function), and global. Results: Follow-up cognitive tests were available in 334 @entity1 after intervention (median, 4.1 years). In multivariate analyses adjusted for confounders, @entity1 allocated to a Mediterranean diet   plus olive oil scored better on the RAVLT (P   =   .049) and Color @entity2205 Test part 2 (P   =   .04) compared with controls; no between-group differences were observed for the other cognitive tests. Similarly adjusted cognitive composites (mean z scores with 95% CIs) for changes above baseline of the memory composite were 0.04 (-0.09 to 0.18) for the Mediterranean diet plus olive oil, 0.09 (-0.05 to 0.23; P   =   .04 vs controls) for the Mediterranean diet plus nuts, and -0.17 (-0.32 to -0.01) for the control diet. Respective changes from baseline of the frontal cognition composite were 0.23 (0.03 to 0.43; P   =   .003 vs controls), 0.03 (-0.25 to 0.31), and -0.33 (-0.57 to -0.09). Changes from baseline of the global cognition composite were 0.05 (-0.11 to 0.21; P   =   .005 vs controls) for the Mediterranean diet plus olive oil, -0.05 (-0.27 to 0.18) for the Mediterranean diet plus nuts, and -0.38 (-0.57 to -0.18) for the control diet. All cognitive composites significantly (P   <   .05) decreased from baseline in controls. Conclusions and Relevance: In an older population, a Mediterranean diet supplemented with olive oil or nuts is associated with improved cognitive function. Trial Registration: isrctn.org Identifier: ISRCTN35739639.

title: Mediterranean Diet and Age-Related XXXX : A Randomized Clinical Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'Participants']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular impairment']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive change', 'cognitive decline']

answer: @entity73 :: (MESH:D003072,Disease) :: ['Cognitive Decline']


abstract: UNASSIGNED: Purpose. To examine causes as well as extent of delay in diagnosis and treatment of primary @entity1538 @entity1 in a sample of Egyptians. @entity1 and Methods. 440 @entity1 with primary @entity1538 were interviewed to evaluate delay in their diagnosis and treatment. The extent and cause of delay were investigated. The total delay interval, if any, was correlated with socioeconomic and other factors. Results. The median total delay was one year, with 50% of @entity1 having a total delay of 1 year or less, of which 25% exhibited zero total delay. 25% of @entity1 had a delay ranging from 1 to 3 years, and 25% had a total delay ranging from 3 to 27 years. Diagnostic delay accounted for 43.03% of cases. Longer delays were met in @entity1 with certain socioeconomic factors. @entity1 with a positive family history of @entity726 displayed @entity245 periods. Conclusion. Significant delay in the diagnosis and treatment of @entity726 was found. Poor socioeconomic status seems to hinder timely diagnosis and treatment of @entity725 . Certain socioeconomic factors seem to correlate with the extent of delay. More effort is thus needed to subsidize the cost of investigations and treatment for @entity726 @entity1 .

title: Examining Delay Intervals in the Diagnosis and Treatment of Primary Open XXXX in an Egyptian Population and Its Impact on Lifestyle.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open angle glaucoma']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['shorter delay']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

answer: @entity726 :: (MESH:D005901,Disease) :: ['Angle Glaucoma']


abstract: UNASSIGNED: Injuries to peripheral nerves and/or skeletal muscle can cause scar tissue formation and loss of function. The focus of this article is the creation of a conductive, biocompatible scaffold with appropriate mechanical properties to regenerate skeletal muscle. @entity18694 ( @entity18695 ) nanoparticles (Np) were electrospun with @entity4351 (PCL) to form conductive scaffolds. During electrospinning, ribboning, larger fiber diameters, and unaligned scaffolds were observed with increasing @entity18695 amounts. To address this, @entity18695 Np were sonicated prior to electrospinning, which resulted in decreased conductivity and increased mechanical properties. Multi-walled @entity505 nanotubes (MWCNT) were added to the 1:2 solution in an effort to increase conductivity. However, the addition of MWCNT had little effect on scaffold conductivity, and the elastic modulus and yield stress of the scaffold increased as a result. @entity35 muscle cells attached and were active on the 1-10, 1-2, 3-4, and 1-1 PCL- @entity18695 scaffolds; however, the 3-4 scaffolds had the lowest level of metabolic activity. Although the scaffolds were cytocompatible, further development of the fabrication method is necessary to produce more highly aligned scaffolds capable of promoting skeletal muscle cell alignment and eventual regeneration.    2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2015.

title: @entity18694 nanoparticle and XXXX electrospun scaffold characterization for skeletal muscle regeneration.

entities_list: @entity18694 :: ('MESH:C121383', 'Chemical') :: ['Poly(3,4-ethylenedioxythiophene)']

entities_list: @entity4351 :: ('CHEBI:60736', 'Chemical') :: ['poly(  -caprolactone)']

answer: @entity4351 :: (CHEBI:60736,Chemical) :: ['poly(  -caprolactone)']


abstract: BACKGROUND: Multimodal treatment of @entity1 with @entity463 ( @entity463 ) allows an increasing number of @entity1 to survive beyond one year. On account of various neurological and @entity73 , however, these @entity1 may not benefit in terms of quality of life (QOL). We evaluated the subjective QOL, clinical psychophysiological and cognitive functions in @entity1 with @entity463 surviving 18 months after diagnosis. @entity1 AND METHODS: Thirteen @entity1 underwent psychophysiological and psychometric measurements for central-nervous activation, habituation of skin-conductance reaction, crystallized intelligence, verbal and psychovisual memory. QOL was assessed by the symptom check-list for somatization (SCS-Score). RESULTS: We found @entity73 such as central-nervous deactivation (n = 9) or high activation (n = 3), psychovegetative overexcitement (n = 3) or attenuation (n = 1), reduced verbal (n = 5) and/or psychovisual (n = 5) memory and loss in attention (n = 7) or concentration (n = 5). Severe physical symptoms (grade 5) were @entity1295 , @entity410 , @entity10 , @entity390 and micturition difficulties. Eleven @entity1 expressed high satisfaction with life in general, whereas only 4 were satisfied with their general state of health. All @entity1 were independent and 8 @entity1 returned to work. CONCLUSION: Despite various psychophysiological and @entity73 , subjective QOL appears mostly unaffected in this @entity1 setting.

title: Psychometric- and quality-of-life assessment in long-term XXXX survivors.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['convulsion']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['various impairments', 'cognitive impairments', 'psychophysiological impairments']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM']

answer: @entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']


abstract: It has been demonstrated that for a nonpathogenic, leaf-associated bacterium, effectiveness in the control of bacterial speck of @entity523 is correlated with the similarity in the nutritional needs of the nonpathogenic bacterium and the pathogen @entity3437 . tomato. This relationship was investigated further in this study by using the pathogen @entity7591 , the causal agent of bacterial spot of @entity523 , and a collection of nonpathogenic bacteria isolated from @entity523 foliage. The effects of inoculation of @entity523 plants with one of 34 nonpathogenic bacteria prior to inoculation with the pathogen @entity7591 were quantified by determining (i) the reduction in disease severity (number of lesions per square centimeter) in greenhouse assays and (ii) the reduction in leaf surface pathogen population size (log(10) of the number of CFU per leaflet) in growth chamber assays. Nutritional similarity between the nonpathogenic bacteria and @entity7591 was quantified by using either niche overlap indices (NOI) or relatedness in cluster analyses based upon in vitro utilization of @entity505 or @entity1568 sources reported to be present in @entity523 tissues or in Biolog GN plates. In contrast to studies with @entity3437 . tomato, nutritional similarity between the nonpathogenic bacteria and the pathogen @entity7591 was not correlated with reductions in disease severity. Nutritional similarity was also not correlated with reductions in pathogen population size. Further, the percentage of reduction in leaf surface pathogen population size was not correlated with the percentage of reduction in disease severity, suggesting that the epiphytic population size of @entity7591 is not related to disease severity and that @entity7591 exhibits behavior in the phyllosphere prior to lesion formation that is different from that of @entity3437 pv. @entity523 .

title: Nutritional similarity between leaf-associated nonpathogenic bacteria and the pathogen is not predictive of efficacy in biological control of bacterial spot of XXXX .

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity3437 :: ('317', 'Species') :: ['P. syringae', 'Pseudomonas syringae pv', 'P. syringae pv']

entities_list: @entity7591 :: ('456327', 'Species') :: ['Xanthomonas campestris pv. vesicatoria', 'X. campestris pv. vesicatoria']

answer: @entity523 :: (4081,Species) :: ['tomato']


abstract: The effect of mesenchymal stem cells (MSCs) on the growth of @entity5 is ambiguous. MSCs derived from different tissues stimulate growth of some @entity5 types and exert antitumor effects on the other. Several recent reports have shown that crosstalk between @entity5 cells and MSCs contribute to these effects. The aim of this work was to study the effects of MSCs derived from fetal tissues on the proliferative activity of @entity11 cells in conditions of prolonged co-cultivation. We have analyzed the proliferative activity of @entity11 cells exposed to @entity558 ( @entity558 ) from MSCs derived from fetal bone marrow (FetMSC) and fetal muscle (M-FetMSC) as well as to @entity558 from co-cultivation of the fetal MSCs with @entity1 @entity11 cells. As a comparison, the influence of @entity558 from adult dermal fibroblasts (DFs) was examined in identical experiments. Using @entity98 assay, we have found that @entity558 from both the fetal MSCs and adult DFs (without their co-culturing with @entity11 cells) had no effect on @entity1 and A172 @entity11 cell proliferation. However, @entity558 from early co-cultures (3-9 days) of @entity1 cells with FetMSC or M-FetMSC exerted stimulatory effect on @entity1 cell proliferation up to 2.3-fold increase, while @entity558 obtained later from the same co-cultures (15-21 days) had inhibitory effect on the proliferation up to arrest of cell division. Analogous experiments with adult DFs have revealed a persistent stimulation of @entity1 cell proliferative activity for all 21 days of co-culturing. Immunofluorescence analysis revealed a reduction in the expression of cell cycle protein @entity4910 in @entity1 cells after their treatment with @entity558 taken from 21-days co-cultures of @entity1 cells with FetMSC or M-FetMSC. In contrast, @entity558 from 21-days co-cultures of @entity1 cells with DFs did not decrease the expression of @entity4910 . These results show that fetal MSCs have dual effect on @entity11 cell proliferation. In spite of the earlier stimulatory effect on the proliferative activity, prominent inhibition of @entity11 cell proliferation was observed after three week co-culturing of @entity11 cells with fetal MSCs. This is the first report demonstrating reversion of @entity5 cell proliferative program during co-culturing with MSCs for a long time. These data suggest that @entity558 obtained at different time points of cell co-culturing can be used in the modeling of prolonged cellular crosstalk.

title: [Influence of @entity1 fetal mesenchymal stem cells on XXXX cell proliferation. A consequence of cellular crosstalk].

entities_list: @entity558 :: ('MESH:C536528', 'Disease') :: ['CM', 'conditioned medium']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['various tumors', 'tumor']

answer: @entity11 :: (MESH:D005910,Disease) :: ['glioma']


abstract: OBJECTIVES: This study compared the relative efficiency of lumbar x-ray and rapid magnetic resonance (MR) imaging for diagnosing @entity1643 (LBP) in primary care @entity1 . DESIGN: We developed a decision model with Markov state transitions to calculate the cost per case detected and cost per quality-adjusted life year (QALY) of rapid MR imaging. Model parameters were estimated from the medical literature. The costs of x-ray and rapid MR were calculated in an activity-based costing study. SETTING AND @entity1 : A hypothetical cohort of primary care @entity1 with LBP referred for imaging to exclude @entity5 as the cause of their @entity158 . MAIN RESULTS: The rapid MR strategy was more expensive due to higher initial imaging costs and larger numbers of @entity1 requiring conventional MR and biopsy. The overall sensitivity of the rapid MR strategy was higher than that of the x-ray strategy (62% vs 55%). However, because of low pre-imaging prevalence of @entity1643 , this generates <1 extra case per 1,000 @entity1 imaged. Therefore, the incremental cost per case detected using rapid MR was high ( 213,927). The rapid MR strategy resulted in a small increase in quality-adjusted survival (0.00043 QALYs). The estimated incremental cost per QALY for the rapid MR strategy was  296,176. CONCLUSIONS: There is currently not enough evidence to support the routine use of rapid MR to detect @entity5 as a cause of LBP in primary care @entity1 .

title: Rapid magnetic resonance imaging for diagnosing XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['cancer-related LBP', 'cancer-related low back pain']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity1643 :: (MESH:D017116,Disease) :: ['cancer-related low back pain']


abstract: Fifty of 66 @entity1 whose thyroid function had previously been assessed 7-139 months after irradiation for @entity978 were re-evaluated 35 +/- 3 months later. They could be divided into three groups: those whose thyroid function had been normal in the first study (N = 26), those who had had asymptomatic @entity1374 (N = 19), and those in whom evidence of @entity2743 had developed (N = 5). The 26 @entity1 who had been euthyroid when first studied had developed significant increases in mean thyroid-stimulating hormone (TSH) levels (basal and following thyrotrophin releasing hormone) without changes in mean free thyroxine index (FTI). In three of these @entity1 , each studied within six years of irradiation, basal TSH had risen to hypothyroid levels. There were no significant changes in mean FTI or basal and peak TSH in 19 @entity1 who had demonstrated @entity1374 in the first study. The cumulative incidence of @entity1374 in the total cohort is now 30/66 (45%) but only one of these 30 has developed clinical @entity1375 . Five @entity1 developed evidence of @entity2743 . Two @entity1 with @entity2743 and one with euthyroid @entity2743 were found in the initial study. On re-evaluation, a third @entity1 had developed frank @entity2743 and another euthyroid @entity2743 , giving a cumulative incidence of @entity2743 of 5/66 (7%). Three of these five were HLA-DR3 and three had measurable thyrotrophin binding inhibiting immunoglobulins. We conclude that @entity1374 continues to develop within six years of mantle irradiation in adults but once established appears to remain stable.(ABSTRACT TRUNCATED AT 250 WORDS)

title: @entity1375 and XXXX after mantle irradiation: a follow up study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism']

entities_list: @entity2743 :: ('MESH:D006111', 'Disease') :: ["Graves' disease", 'thyrotoxicosis']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's disease"]

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['impaired thyroid reserve']

answer: @entity2743 :: (MESH:D006111,Disease) :: ['Graves' disease']


abstract: BACKGROUND: Prevalence and causes of sex-based differences in morbidity and mortality secondary to @entity65 remain controversial. @entity6949 ( @entity6949 ) is a sensitive and specific marker for @entity296 . Serial @entity6949 measurements have been used to identify perioperative @entity296 . OBJECTIVE: To determine whether sex influences the extent of @entity296 during cardiac surgery, we measured perioperative @entity6949 in male and female @entity1 . DESIGN: A total of 17 male and 17 female @entity1 were prospectively studied in an age- and case-matched manner. Arterial @entity6949 were obtained preinduction, 30 mins after the application of the aortic cross-clamp, at arrival to the intensive care unit, and on postoperative day 1. SETTING: Tertiary cardiac surgery center at a major teaching hospital. RESULTS: There was no difference between @entity1 and @entity1 in body mass index (kg/m2), duration of cardiopulmonary bypass, and aortic cross-clamp times. Preoperative @entity6949 measurements were similar in @entity1 (0.24 +/- 0.15 ng/mL) and @entity1 (0.25 +/- 0.13 ng/mL, mean +/- sem). The maximum serum @entity6949 occurred on postoperative day 1 in all @entity1 , and it was 3-fold higher in @entity1 (18.5 +/- 5.7 ng/mL) compared with @entity1 (6.4 +/- 1.0 ng/mL). CONCLUSIONS: @entity1 had markedly higher serum @entity6949 compared with @entity1 , although they were case matched with respect to age and cardiac risk factors. Our results may suggest there may be sex-related differences in the myocardial response to @entity63 and reperfusion injury or intrinsic differences between the male and female myocardium.

title: Sex-based differences in serum @entity6949 , a specific marker for XXXX , after cardiac surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Men', 'men']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial injury', 'myocardial cell injury']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity6949 :: ('7137', 'Gene') :: ['cTnI', 'Cardiac troponin I']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity296 :: (MESH:D009202,Disease) :: ['myocardial injury']


abstract: OBJECTIVE/BACKGROUND: Mycobacterium species comprise one of the most frequently-reported causative agents in @entity75 of fish. Also, mycobacteria have been documented as fish-born zoonoses. Ornamental aquaria, commercial aquaculture, and wild fisheries therefore produce a potential risk of @entity281 for @entity1 through physical contact and consumption of fishes. A number of fish @entity4593 and fish-born zoonotic cases have been reported to date in Iran. METHODS: In order to examine the frequency of mycobacteria existence in fish supplied to the public in seafood retail outlets, whole fresh fish from cold water (n=50) and tropical (n=50) audible fish were obtained from five stores in Karaj, the central city of Alborz province. The head, tail, and offal of these fish were sampled during the necropsy and used for mycobacterial culture on Lowenstein-Jensen slopes. RESULTS: In total, 15 acid-fast isolates were collected including 10 from tropical fish. The 16S ribosomal RNA and @entity1879 genes of all isolates were polymerase chain reaction amplified and sequenced. @entity33602 was the most frequent mycobacterium identified in the study panel according to the Basic Local Alignment Search Tool search results. Work is still ongoing to characterize the other cultured mycobacterial isolates. CONCLUSION: The detection of 15 culturable mycobacterial isolates from 100 audible fish is an indication of bacteria highly active in the colonization in fish populations. Assessing the potential zoonotic risk raised from exposure of @entity1 to fishes in Iran demands search for evidence of linkages between mycobacteria infecting @entity1 cases and fishes.

title: Frequency of XXXX in retailed fish in Karaj: An Iranian perspective.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['granulomatous lesions']

entities_list: @entity4593 :: ('MESH:D009165', 'Disease') :: ['mycobacteriosis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity33602 :: ('1766', 'Species') :: ['Mycobacterium fortuitum']

answer: @entity281 :: (MESH:D007239,Disease) :: ['mycobacterial infections']


abstract: BACKGROUND: The prognosis of @entity1 with high risk @entity2590 ( @entity2590 ) (i.e., @entity7139 [ @entity7139 ] and @entity7139 in transformation [ @entity7139 -t]) usually is poor. The combination of @entity3118 , @entity2592 , and @entity1261 ( @entity1261 ) (FLAG regimen) has been reported to be effective in @entity1 with these diseases. METHODS: Forty-two @entity1 (32 with @entity7139 -t and 10 with @entity7139 ) were treated with the FLAG regimen. The median age was 61 years (range, 27-74 years). Forty @entity1 were diagnosed with primary @entity2590 and 2 @entity1 had treatment-related @entity2590 . Induction therapy was comprised of the FLAG regimen, whereas consolidation therapy included @entity8779 and @entity2592 . @entity1 with a compatible donor and who were age < 50 years were scheduled to undergo an allogeneic bone marrow transplantation (BMT), whereas for those @entity1 without a donor and who were age < 60 years autologous BMT with peripheral blood stem cells mobilized by the consolidation regimen plus @entity1261 was planned. RESULTS: Complete remission (CR) was achieved in 31 of 42 @entity1 (74%; 95% confidence interval, 60-87%). @entity204 during induction therapy occurred in 4 @entity1 (9%) whereas 7 @entity1 (17%) were resistant to the FLAG regimen. @entity137 from the consolidation regimen was negligible. All @entity1 age < 50 years and achieving CR were eligible for allogeneic BMT procedures, with early recurrence being the only reason for exclusion. The median overall survival and disease free survival were 13 months and 18 months, respectively. @entity1 with favorable cytogenetics had a significantly better outcome compared with those @entity1 with an adverse karyotype. CONCLUSIONS: The FLAG regimen is effective in @entity1 with high risk @entity2590 as well as in @entity1 age > 60 years. The @entity137 of the regimen is low and the majority of @entity1 are eligible to undergo allogeneic BMT procedures after induction/consolidation therapy.

title: @entity3118 , XXXX , and @entity1261 for the treatment of high risk @entity2590 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity7139 :: ('MESH:D000754', 'Disease') :: ['RAEB', 'refractory anemia with excess of blasts']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity']

entities_list: @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte-colony stimulating factor']

entities_list: @entity8779 :: ('MESH:D015255', 'Chemical') :: ['idarubicin']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndromes', 'MDS']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

answer: @entity2592 :: (MESH:D003561,Chemical) :: ['cytarabine']


abstract: 2013 was another exciting year for @entity566 in general and Clinical and Experimental @entity566 in particular. In the field of @entity565 and @entity2490 there continued to be a focus on heterogeneity and phenotypes with increasing use of bio-statistical techniques to determine clusters of similar populations. @entity28 and @entity117 associated disease are intriguing associations with @entity565 which were explored in a number of papers. We published a number of excellent papers on mechanisms of airway inflammation and how this relates to physiology, pathology, genetics and biomarkers in both @entity1 and experimental model systems. In terms of mechanisms there is less on individual cell types in @entity56 at the moment, but the immunology of @entity56 continued to fascinate our authors. Another area that was popular both in the mechanisms and epidemiology sections were early life events and how these lead to @entity56 , with an increasing focus on the role of the microbiome and how this influences immune tolerance. In the clinical @entity566 section oral immunotherapy for @entity5419 is clearly a major topic of interest at the moment as was in vitro testing to distinguish between sensitization and @entity56 . There was less on inhalant @entity566 this year, but a good representation from the @entity56 including some interesting work on non-IgE mediated mechanisms. In the allergen section important new allergens continue to be discovered, but the major focus as in the last couple of years was on working out how component resolved approaches can improve diagnosis and management of food and venom @entity566 . This article is protected by copyright. All rights reserved.

title: Developments in the field of @entity566 in 2013 through the eyes of Clinical and Experimental XXXX .

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity']

entities_list: @entity5419 :: ('MESH:D005512', 'Disease') :: ['food allergy']

entities_list: @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy', 'Allergy']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic disease', 'drug allergy community']

answer: @entity566 :: (MESH:D006967,Disease) :: ['Allergy']


abstract: CONTEXT: Death @entity148 (DA) is related to awareness of the reality of dying and @entity204 and can be negatively related to a @entity1 's @entity458 . Physicians' DA also may influence their care for @entity1 @entity204 . Doctors face @entity204 in a professional context for the first time at medical school, but knowledge about DA among medical students is limited. OBJECTIVES: This study examined medical students' DA in relation to: 1) its severity, gender differences, and trajectory during medical education and 2) its associations with students' attitudes toward palliative care and their @entity458 . METHODS: Four cohorts of core science and four cohorts of clinical students at the University of Cambridge Medical School took part in a questionnaire survey with longitudinal follow-up. Students who provided data on the revised Collett-Lester Fear of Death Scale were included in the analysis (n  =  790). RESULTS: Medical students' DA was moderate, with no gender differences and remained very stable over time. High DA was associated with higher @entity308 and @entity148 levels and greater concerns about the personal impact of providing palliative care. CONCLUSION: The associations between high DA and lower @entity458 and negative attitudes toward palliative care are concerning. It is important to address DA during medical education to enhance student's @entity458 and the quality of their future palliative care provision.

title: Medical Students' Death XXXX : Severity and Association With Psychological Health and Attitudes Toward Palliative Care.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'person']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological health']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['approaching death', 'death']

answer: @entity148 :: (MESH:D001008,Disease) :: ['Anxiety']


abstract: PURPOSE: The purpose of this study was to assess the overall results of recipients undergoing transplantation for @entity2876 ( @entity2876 ), according to age, surgical techniques, and transplant eras, and to identify the prognostic factors affecting outcome. METHODS: Between 1984 and 2000, 328 pediatric recipients with @entity2876 who underwent orthotopic liver transplantation (OLT) were reviewed. Median age at OLT was 1.5 years (range, 0.4-14.5 years). Kasai hepatoportoenterostomy (KHPE) had been previously performed in 285 (87%) @entity1 . Regarding surgical techniques, 125 (38%) @entity1 received a whole-liver graft, 128 (39%) received a reduced-size graft, 16 (5%) received a split-liver graft, and 59 (18%) received a living-related (LR) donor graft. RESULTS: Overall actuarial @entity1 survivals were 87%, 83%, and 81% at 1, 5, and 10 years, respectively. One-year @entity1 survivals in @entity1 undergoing transplantation at the different age ranges were 85% (under 1 year), 86% (1-3 years), 83% (3-6 years), 100% (6-10 years), and 100% (beyond 10 years) (not significant). One-year @entity1 survivals for the different transplant eras were 75% (1984-1988), 85% (1989-1992), 93% (1993-1996), and 98% (1997-2000) (P=0.0001). Multivariate analysis demonstrated that pretransplant recipient weight (P=0.004), indication for OLT (P=0.083), and age at OLT (P=0.024) predicted @entity1 survival. The type of baseline @entity9909 ( @entity1140 ) and the age at OLT (beyond 6 years) were significantly associated with a better graft survival. CONCLUSIONS: Best results in @entity1 undergoing transplantation beyond 6 years indicate the importance of performing a KHPE as the first therapeutic step in @entity2876 ; innovative surgical techniques, particularly LR donor graft, allowed successful transplantation in @entity1 with early failure of KHPE.

title: Pediatric liver transplantation for XXXX : results of primary grafts in 328 recipients.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient', 'infants']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

entities_list: @entity9909 :: ('23523', 'Gene') :: ['calcineurin inhibitor']

entities_list: @entity2876 :: ('MESH:D001656', 'Disease') :: ['BA', 'biliary atresia']

answer: @entity2876 :: (MESH:D001656,Disease) :: ['biliary atresia']


abstract: @entity14746 is a commonly used non-sedating antihistamine for the symptomatic relief of @entity56 . Few reports exist on the result of @entity1445 in @entity1 . We would like to report the result of a 12 fold @entity1445 of @entity14746 in a four-year-old- @entity1 (weight 20 kg) who accidentally ingested 60 mg. Vomiting was induced 1 1/2 hour after ingestion in the out- @entity1 clinic at the local hospital because of severe drowsiness. Due to continued lethargy he was transferred to the referral paediatric department for further observation. He was fully recovered after five to six hours without any treatment. Electrocardiographic monitoring was normal. Five incidents of @entity14746 @entity1445 in @entity1 have been reported previously. Drowsiness and sedation were observed, but no other side effects. The risk of @entity299 related to an @entity1445 of @entity14746 is extremely small. A certain degree of sedation is to be expected.

title: [Accidental XXXX poisoning in a four-year-old @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient', 'boy']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic reactions']

entities_list: @entity14746 :: ('MESH:D017332', 'Chemical') :: ['Cetirizine', 'cetirizine']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

answer: @entity14746 :: (MESH:D017332,Chemical) :: ['cetirizine']


abstract: BACKGROUND: Cancer-related @entity158 is highly prevalent among outpatients with metastatic @entity0 affecting their health-related quality of life (HRQoL). This study evaluates potential effects of comprehensive pharmacologic @entity5 therapy (CPT) on HRQoL. @entity1 AND METHODS: 52 outpatients with metastatic @entity0 undergoing palliative chemotherapy participated. 28 @entity1 suffering from moderate to severe @entity5 were offered CPT. 13 @entity1 participated (intervention group), and 15 declined participation (control group). HRQoL was assessed with the Quality of Life Questionnaire (EORTC QLQ-C30) and the breast module QLQ-BR23 at baseline and after 3 weeks. RESULTS: At baseline, 83% of the @entity1 experienced @entity5 -related @entity158 , of whom 35% were not prescribed any @entity158 medication. HRQoL of all @entity1 was reduced compared to reference scores. After CPT, the intervention group reported significantly @entity158 and improvement in several HRQoL subscales (Global QoL, Emotional Functioning, Physical Functioning, Future Perspective, @entity22 ). The control group did not change significantly. CONCLUSION: This study emphasizes the demand for sufficient @entity158 management in palliative @entity0 outpatients. The combination of @entity1191 as a guidance for the pharmacological aspects of @entity5 management and the EORTC QLQ-C30 as an assessment and surveillance tool appears to be a method that warrants further research.

title: Improvements in health-related quality of life by comprehensive XXXX therapy: a pilot study with @entity0 outpatients under palliative chemotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cancer pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['alleviated pain', 'pain']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['Sleeplessness']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer pain']


abstract: PURPOSE: Babies born in the hospital where they obtain definitive surgical care do not require transportation between institutions and may have shorter time to surgical intervention. Whether these differences result in meaningful improvement in outcomes has been debated. A multi-institutional retrospective study was performed comparing outcomes based on birthplace. METHODS: Six institutions within the PedSRC reviewed @entity1 born with @entity6675 from 2008 to 2013. Birthplace, perinatal, and postoperative data were collected. Based on the P-NSQIP definition, inborn was defined as birth at the pediatric hospital where repair occurred. The primary outcome was days to full enteral nutrition (FEN; 120kcal/kg/day). RESULTS: 528 @entity1 with @entity6675 were identified: 286 inborn, 242 outborn. Days to FEN, time to bowel coverage and abdominal wall closure, primary closure rate, and length of stay significantly favored inborn @entity1 . In multivariable analysis, birthplace was not a significant predictor of time to FEN. Gestational age, presence of @entity1146 or @entity39 , primary closure rate, and time to abdominal wall closure were significant predictors. CONCLUSIONS: Inborn @entity1 had bowel coverage and definitive closure sooner with fewer days to full feeds and shorter length of stay. Birthplace appears to be important and should be considered in efforts to improve outcomes in @entity1 with @entity6675 .

title: Improving XXXX outcomes: Does birth place matter?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'infants']

entities_list: @entity6675 :: ('MESH:D020139', 'Disease') :: ['gastroschisis']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

answer: @entity6675 :: (MESH:D020139,Disease) :: ['gastroschisis']


abstract: UNASSIGNED: Studies have attempted to categorize @entity1 cranial asymmetry in a variety of ways using both observational and quantitative techniques, but none have created a clinical tool that can serve as a treatment guide based on clinical outcomes. In 2006, a research team from @entity1 's Healthcare of Atlanta published the results of a prospective analysis of 224 @entity1 with cranial asymmetries and their treatment outcomes. As a continuation of the previous work, the researchers have identified a @entity9283 severity scale based on those outcomes to assist medical professionals who treat @entity1 with @entity129 . Our hypothesis is to validate the proposed severity scale that categorizes the clinical presentation and severity of @entity9283 .Of the 224 @entity1 enrolled, 207 @entity1 were placed in an experimental group and 17 @entity1 who refused treatment were placed in a control group. Digital head shape data were collected. Cross-correlation matrices were computed across variables and regression models resulted in the identification of 5 meaningful variables. A 5-level clinical classification scale was created. Five 1*5 analyses of variance were computed to compare each classification level.Four of the 5 analyses of variance identified significant overall effects for classification. A model was developed from the empirical data and the model was tested for accuracy, resulting in 12.1% overall error. The model was validated for both experimental and control groups.The results show that the severity scale is a meaningful outcome-based scale that assists clinicians in developing a treatment plan for treating @entity9283 . The scale has been validated across a large heterogeneous study sample.

title: XXXX Severity Scale to Aid in Clinical Treatment Recommendations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Children', 'infant']

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial abnormalities']

entities_list: @entity9283 :: ('MESH:D059041', 'Disease') :: ['plagiocephaly']

answer: @entity9283 :: (MESH:D059041,Disease) :: ['Plagiocephaly']


abstract: Bacterial cell-cell communication or quorum sensing (QS) is a biological process commonly described as allowing bacteria belonging to a same pherotype to coordinate gene expression to cell density. In Gram-positive bacteria, cell-cell communication mainly relies on cytoplasmic sensors regulated by secreted and re-imported signaling peptides. The Bacillus quorum sensors Rap, NprR, and PlcR were previously identified as the first members of a new protein family called RNPP. Except for the Rap proteins, these RNPP regulators are transcription factors that directly regulate gene expression. QS regulates important biological functions in bacteria of the @entity5259 group. PlcR was first characterized as the main regulator of virulence in @entity11137 and @entity5259 . More recently, the PlcR-like regulator PlcRa was characterized for its role in @entity462 metabolism and in resistance to oxidative stress. The NprR regulator controls the necrotrophic properties allowing the bacteria to survive in the infected host. The Rap proteins negatively affect sporulation via their interaction with a phosphorelay protein involved in the activation of Spo0A, the master regulator of this differentiation pathway. In this review we aim at providing a complete picture of the QS systems that are sequentially activated during the lifecycle of @entity5259 and @entity11137 in an insect model of @entity281 .

title: Quorum sensing in XXXX is required for completion of a full infectious cycle in the insect.

entities_list: @entity5259 :: ('1396', 'Species') :: ['B. cereus', 'Bacillus cereus']

entities_list: @entity11137 :: ('1428', 'Species') :: ['B. thuringiensis']

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity11137 :: (1428,Species) :: ['Bacillus thuringiensis']


abstract: In post-traumatic @entity5300 in adults, early repair will necessitate a variety of nerve grafting and nerve transfer procedures. In complete palsies, a graft is performed from a radicular stump, using intercostal nerve transfers, @entity2483 . This will provide @entity14228 and extension in 75% of cases, and shoulder abduction or rotation in 50% of cases. In the @entity912 , ulnar-biceps transfer is the standard procedure. Grafting from a ruptured cervical root, when available, is performed to reanimate the shoulder. In @entity2483 palsies, extension of the wrist and fingers is provided by tendon transfers. In chronic palsies, @entity14228 and extension loss is treated by means of free muscle transfers, (latissimus dorsi or gracilis) combined with nerve transfers (intercostals or spinal accessory). Secondary procedures are routinely necessary following recovery of @entity14228 . For the shoulder-humeral shaft osteotomy or fusion, for the hand-cosmetic fusion of the wrist and distal radio-ulnar joint in the prone position, or palliative treatment in case of partial recovery. For such weak " @entity8566 ", we have developed a specific hierarchical functional scale, useful for surgical decisions.

title: [ XXXX in adults with radicular lesions, general concepts, diagnostic approach and results ].

entities_list: @entity14228 :: ('MESH:C535618', 'Disease') :: ['elbow flexion']

entities_list: @entity5300 :: ('MESH:D020516', 'Disease') :: ['brachial plexus lesions']

entities_list: @entity8566 :: ('MESH:D060831', 'Disease') :: ['plexic hands']

entities_list: @entity2483 :: ('MESH:C566443', 'Disease') :: ['partial cross C7 transfer, and the distal spinal accessory nerve', 'C5 C6 and C7']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['upper type palsies']

answer: @entity5300 :: (MESH:D020516,Disease) :: ['Brachial plexus palsy']


abstract: Lipopolysaccharide (LPS) administration induces hypothalamic @entity842 (NO); NO is antipyretic in the preoptic area (POA), but its mechanism of action is uncertain. LPS also stimulates the release of preoptic @entity1063 (NE), which mediates fever onset. Because NE upregulates NO synthases and NO induces cyclooxygenase (COX)-2-dependent @entity1421 , we investigated whether NO mediates the production of this central fever mediator. Conscious @entity840 with intra-POA microdialysis probes received LPS intravenously (2 mug/kg) and, thereafter, an NO donor (SIN-1) or scavenger ( @entity6706 ) intra-POA (20 mug/mul each, 2 mul/min, 6 h). Core temperature (T(c)) was monitored constantly; dialysate NE and @entity1421 were analyzed in 30-min collections. To verify the reported involvement of alpha(2)-adrenoceptors (AR) in @entity1421 production, @entity1338 (alpha(2)-AR agonist, 2 mug/mul) was microdialyzed with and without SIN-1 or @entity6706 . To assess the possible involvement of oxidative NE and/or NO products in the demonstrated initially @entity31962 -independent POA PGE(2) increase, @entity12919 (an antioxidant, 3 mug/mul) was microdialyzed, and POA PGE(2), and T(c) were determined. SIN-1 and @entity6706 reduced and enhanced, respectively, the rises in NE, @entity1421 , and T(c) produced by intravenous LPS. Similarly, they prevented and increased, respectively, the delayed elevations of @entity1421 and T(c) induced by intra-POA @entity1338 . @entity12919 prevented the LPS-induced elevation of @entity1421 , but not of T(c). We conclude that the antipyretic activity of NO derives from its inhibitory modulation of the LPS-induced release of POA NE. These data also implicate free radicals in POA @entity1421 production and raise questions about its role as a central LPS fever mediator.

title: Preoptic @entity842 attenuates endotoxic fever in @entity840 by inhibiting the POA release of XXXX .

entities_list: @entity6706 :: ('MESH:C079393', 'Chemical') :: ['carboxy-PTIO']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity1338 :: ('MESH:D003000', 'Chemical') :: ['clonidine']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity1063 :: (MESH:D009638,Chemical) :: ['norepinephrine']


abstract: OBJECTIVE: Question prompt lists (QPLs) and consultation audio-recordings (CARs) are two communication strategies that can assist @entity5 @entity1 in understanding and recalling information. We aimed to explore clinician and organisational barriers and facilitators to implementing QPLs and CARs into usual care. METHODS: Semi-structured interviews with twenty clinicians and senior hospital administrators, recruited from four hospitals. Interviews were recorded, transcribed verbatim and thematic descriptive analysis was utilised. RESULTS: CARs and QPLs are to some degree already being initiated by @entity1 but not embedded in usual care. Systematic use should be driven by @entity1 preference. Successful implementation will depend on minimal burden to clinical environments and feedback about @entity1 use. CARs concerns included: medico-legal issues, ability of the CAR to be shared beyond the consultation, and recording and storage logistics within existing medical record systems. QPLs issues included: applicability of the QPLs, ensuring @entity1 who might benefit from QPL's are able to access them, and limited use when there are other existing communication strategies. CONCLUSIONS: While CARs and QPLs are beneficial for @entity1 , there are important individual, system and medico-legal considerations regarding usual care. PRACTICE IMPLICATIONS: Identifying and addressing practical implications of CARs and QPLs prior to clinical implementation is essential.

title: Barriers and facilitators to the implementation of audio-recordings and question prompt lists in XXXX care consultations: A qualitative study.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: Some @entity1 with @entity3964 infections develop @entity6197 , @entity649 , and shock and ultimately die even though drug therapy has eliminated the parasite from the blood, suggesting that a systemic inflammatory response contributes to malarial pathogenesis. @entity2637 -infected @entity19 are a well-recognized model of severe @entity311 (experimental severe @entity311 [ESM]), and infected @entity19 exhibit a systemic inflammatory response. Because platelets are proposed to contribute to ESM and other systemic inflammatory responses, we determined whether platelet adherence contributes to experimental malarial pathogenesis. Indeed, a significant (P < 0.005) increase in the number of rolling and adherent platelets was observed by intravital microscopy in brain venules of @entity2637 -infected @entity19 compared with the number in uninfected controls. P-selectin- or @entity8024 -deficient @entity19 exhibit increased survival after @entity2637 @entity281 . We observed a significant (P < 0.0001) reduction in the morbidity of @entity19 injected with anti- @entity36375 ( @entity36375 or @entity36375 ) monoclonal antibody on day 1 of @entity2637 @entity281 compared with the morbidity of infected controls injected with @entity35 immunoglobulin G. Additionally, @entity1423 and adhesion in brain venules were reduced in @entity2637 @entity19 lacking either P-selectin or @entity8024 or when the platelets were coated with anti- @entity36375 monoclonal antibody. Unlike other inflammatory conditions, we did not detect platelet-leukocyte interactions during @entity2637 @entity311 . Because (i). leukocyte adhesion is not markedly altered in the absence of P-selectin or @entity8024 and (ii). @entity36375 is not an adhesion molecule for parasitized erythrocytes, these findings support the hypothesis that inhibition of platelet adhesion to the brain microvasculature protects against development of malarial pathogenesis.

title: Inhibition of platelet adherence to brain microvasculature protects against severe XXXX @entity311 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet rolling']

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['acute respiratory distress']

entities_list: @entity6197 :: ('MESH:D016779', 'Disease') :: ['cerebral malaria']

entities_list: @entity3964 :: ('5833', 'Species') :: ['Plasmodium falciparum']

entities_list: @entity2637 :: ('5821', 'Species') :: ['Plasmodium berghei', 'P. berghei']

answer: @entity2637 :: (5821,Species) :: ['Plasmodium berghei']


abstract: The Wechsler Memory Scale-Third Edition ( @entity3297 -III) was developed to overcome the limitations of the Wechsler Memory Scale-Revised and is now routinely used for pre-surgical assessment of memory for @entity1 considering elective surgery for the relief of @entity1315 ( @entity1315 ). We investigated the validity of this relatively new measure in a population of @entity1 with resistant @entity1315 . The sample consisted of 99 @entity1 with a diagnosis if @entity1315 in which the epileptogenic focus was clearly identified and localised to either the right or left hemisphere. @entity1 underwent a full neuropsychological assessment as part of their pre-surgical investigation, including the @entity3297 -III. @entity1 with right temporal focus had significantly lower scores on the visual immediate and delayed indices of the @entity3297 -III than they did on the corresponding auditory indices. The left temporal focal @entity302 group, however, showed no significant @entity227 . The overall scores of the @entity3297 -III were significantly lower than the normative data from the @entity2414 samples. Like its predecessor the Wechsler Memory Scale-Revised, the @entity3297 -III has limited value in identifying particular @entity2414 associated with either left and right temporal lobe focus. The results of the @entity3297 -III show that it is capable of lateralising to right @entity73 but is more problematic in the assessment of left @entity73 . The @entity227 has questionable validity. The search for reliable and valid measures to distinguish between left and right temporal @entity302 focus continues.

title: Validation of the Wechsler Memory Scale-III in a population of @entity1 with intractable XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'people']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual verbal discrepancy', 'disparity between auditory and visual scores']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['hemispheric impairment']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['TLE', 'temporal lobe epilepsy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic', 'epilepsy']

entities_list: @entity2414 :: ('MESH:D008569', 'Disease') :: ['WMS-III standardisation', 'memory deficits']

answer: @entity1315 :: (MESH:D004833,Disease) :: ['temporal lobe epilepsy']


abstract: Angiogenesis involves multiple sequential mechanisms stimulating the growth of host endothelium. It occurs in surgical flaps at the interface with the reconstructed wound bed. In this study, concentrations of basic fibroblast growth factor ( @entity540 ) and transforming growth factor-beta 1 (TGF-beta ) were analyzed in sera and wound fluids of 30 @entity1 who underwent surgical treatment with muscle (n = 15) and fasciocutaneous flaps (n = 15). At 12 hours after operation, @entity540 levels in wound fluids of @entity1 with muscle flaps were significantly (p < 0.05) higher than in @entity1 with fasciocutaneous flaps. At 24 and 36 hours after surgical treatment, there was no significant difference between them. Each group showed a significant decrease in @entity540 levels after 24 and 36 hours. In sera, @entity540 was not detectable. The two different groups presented no remarkable difference in TGF-beta concentrations in wound fluids. A correlation between angiogenic factors in sera and wound fluids could not be observed. The results show that angiogenesis is initially more activated in the wound bed of muscle flaps. This might be of great consequence to the healing process and might explain the curative effect of muscle flaps on bradytrophic tissue.

title: Expression of basic fibroblast growth factor and transforming growth factor-Beta 1 in XXXX with fasciocutaneous and muscle flaps.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To examine the feasibility and efficacy of a multifactorial intervention programme directed towards hypercholesterolaemia, smoking, and @entity6 in treated @entity101 @entity1 after more than 3 years' follow-up and to describe the incidence of @entity65 . DESIGN: Open, randomized, parallel-group study with allocation either to a comprehensive multiple risk factor modification programme or to usual care. SETTING: Outpatient clinic in a city hospital. @entity1 : A total of 508 male @entity1 with treated @entity101 , aged 50-72 years, with at least one of the following: serum @entity165 > or = 6.5 mmol L-1, smoking or @entity6 . INTERVENTION: Individually given advice and group meetings based on nutritional advice and behavioral treatment principles. Drug therapy could be instituted to achieve the treatment goals in the intervention group: serum total @entity165 below 6.0 mmol L-1, no smoking, and @entity4051 c below 6.0%. Diastolic blood pressure below 90 mmHg was the treatment goal in both groups. MAIN OUTCOME MEASUREMENTS: Serum @entity165 , HbA1c, diastolic blood pressure, smoking. Cardiovascular end-points were recorded. RESULTS: The net changes were (change intervention--change usual care): serum @entity165 -5.0% (95% confidence interval, -7.6 to -2.3%), 17.6% more stopped smoking (P = 0.04); diastolic blood pressure and @entity4051 c remained unchanged. The incidence of @entity64 was lower in the intervention group compared with the usual-care group: 2.0 and 6.7%, respectively (P = 0.017). CONCLUSION: The intervention programme was comparatively successful with regards to the effects on hypercholesterolaemia and smoking habits. An unexpected decrease in the @entity64 incidence was observed in the intervention group compared with the usual-care group.

title: The efficacy of multiple risk factor intervention in treated XXXX @entity1 during long-term follow up. Risk Factor Intervention Study Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular complications']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertensive']


abstract: OBJECTIVE: To assess the feasibility of @entity515 -laser-endoscopic surgical treatment for large and/or ruptured ectopic pregnancies, and to compare the results with those of microsurgical salpingotomy. DESIGN: A retrospective review of all @entity1 treated for an ectopic pregnancy during a 6-year period, 1984-1989. During 1988 and 1989 treatment was randomized by the day of admission, depending only upon the surgeon in charge, some performing a linear salpingotomy (n = 42) and some a @entity515 -laser laparoscopy (n = 34) in all @entity1 haemodynamically stable. SETTING: Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Leuven. SUBJECTS: 135 @entity1 with ectopic pregnancies of whom 76 were included in the randomized series between 1988 and 1989. Overall 11 were treated by pelvic lavage, 78 by laparotomy and 46 by laparoscopic procedures. MAIN OUTCOME MEASURES: @entity260 , duration of hospital stay. Cumulative pregnancy rates after the procedures. RESULTS: The two groups of @entity1 analysed in the randomized series were comparable for duration of @entity4999 , diameter of the ectopic pregnancy and prevalence of 'ruptured' ectopics, but the duration of stay in hospital was much shorter (mean 2.9, SD 1.8 days) for the 34 @entity1 treated by laparoscopy than for the 42 @entity1 treated by laparotomy (mean 6.8, SD 1.6 days). The postoperative cumulative pregnancy rate was higher in nulliparous @entity1 with a history of @entity249 or @entity4134 ( @entity4134 ), when treated with @entity515 -laser-laparoscopy (P = 0.009). The recurrency rate was low (less than 5% in both groups). Overall in the @entity1 treated by laparotomy, postoperative cumulative pregnancy rates were lower following excision or adnexectomy than after a microsurgical linear salpingotomy (P = 0.01). Four @entity1 treated by laparoscopy required a second procedure. CONCLUSION: Endoscopic treatment of large and/or ruptured ectopic pregnancies is feasible and resulted in a shorter hospital stay and, in nulliparous @entity1 with a history of @entity4134 or @entity249 , in higher cumulative pregnancy rates, than after microsurgical salpingotomies.

title: Conservative laparoscopic treatment of ectopic pregnancies using the XXXX -laser.

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['Postoperative complications']

entities_list: @entity4134 :: ('MESH:D000292', 'Disease') :: ['PID', 'pelvic inflammatory disease']

entities_list: @entity4999 :: ('MESH:C537962', 'Disease') :: ['amenorrhoea']

answer: @entity515 :: (CHEBI:29334,Chemical) :: ['CO2']


abstract: PURPOSE: To investigate the expression and localization of CXCLl6 and its receptor @entity24101 in gingival tissues of @entity1 with @entity7278 and analyze the roles in the occurrence and development of @entity2521 . METHODS: Gingival tissues with moderately severe @entity2521 were collected from 39 @entity1 treated in @entity1 's Hospital of Liaoning Province. Forty @entity1 with healthy gingiva were used as control. The age of the enrolled subjects ranged from 35 to 74 years old. Immunohistochemical technique was applied to detect the expression and localization of CXCLl6 and @entity24101 protein gingival tissues of all subjects. The data was analyzed with SPSS 15.0 software package. RESULTS: Compared with normal group, the expression of CXCLl6 and @entity24101 were significantly up-regulated in @entity1 with @entity2521 (P<0.05). There was a positive relationship between the protein expression of CXCLl6 and @entity24101 in gingival tissues of @entity1 with @entity2521 (r=0.580, P<0.05). CONCLUSIONS: CXCLl6 and @entity24101 may be involved in the development of @entity7278 . The expression of CXCLl6 and @entity24101 may work coordinately to promote the development of @entity7278 . Supported by Science and Technology Planing Projects of Liaoning Province (2013225021).

title: [Expression of CXC chemokine ligand 16 and chemokine receptor 6 in periodontal tissues of @entity1 with moderately severe XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons', 'People']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

entities_list: @entity7278 :: ('MESH:D055113', 'Disease') :: ['chronic periodontitis']

answer: @entity2521 :: (MESH:D010518,Disease) :: ['periodontitis']


abstract: UNASSIGNED: Up to 14% of individuals with @entity1582 develop acquired @entity11888 , which occurs due to adsorption of factor X onto amyloid fibrils. Although baseline factor X levels are not predictive of @entity548 risk in these @entity1 , serious @entity548 can occur, particularly during invasive procedures. Optimal management strategies to attenuate @entity548 risk in these @entity1 are unknown. We describe our experience in the management of acquired @entity11888 , secondary to @entity1582 , in a case series of 3 @entity1 who received prothrombin complex concentrates (PCCs) for treatment and prevention of @entity548 events. We performed a retrospective review extracting information on baseline demographics, laboratory data, pharmacokinetic (PK) studies and clinically documented @entity548 events. Our case series demonstrates that individuals with acquired @entity11888 secondary to @entity2783 have variable laboratory and clinical responses to PCCs. This is likely due to distinct amyloid loads and fibril sequences, leading to different binding avidities for factor X. Our data emphasize the importance of performing PK testing prior to any invasive procedures to determine the dose and frequency interval to achieve adequate factor X levels for hemostasis, given the variable response between individuals. This article is protected by copyright. All rights reserved.

title: Importance of Pharmacokinetic Studies in the Management of Acquired XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic complications', 'bleeding']

entities_list: @entity2783 :: ('MESH:D000686', 'Disease') :: ['amyloidosis']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['systemic AL amyloidosis']

entities_list: @entity11888 :: ('MESH:D005171', 'Disease') :: ['factor X deficiency']

answer: @entity11888 :: (MESH:D005171,Disease) :: ['Factor X Deficiency']


abstract: BACKGROUND AND PURPOSE: Cerebrospinal fluid (CSF) neurofilament light protein ( @entity20698 ) is a promising biomarker of @entity21 and @entity179 . Here CSF lymphocyte subpopulations and antibodies, potential players of @entity179 , are examined in relation to CSF @entity20698 shedding in @entity15 . METHODS: Cerebrospinal fluid @entity20698 from 127 consecutive untreated @entity15 @entity1 was analysed. Samples from 37 age-matched @entity1 with other central nervous system @entity16 ( @entity16 ) were also assessed. CD4+, CD8+, @entity2940 + and @entity1075 + cell subsets were studied by flow cytometry. Oligoclonal IgG and IgM bands (OCMB) against lipids were studied by isoelectric focusing and immunoblotting. These data were analysed in relation to clinical and magnetic resonance imaging features. RESULTS: A CSF @entity20698 cut-off value of 900  ng/l (mean  +  3 SD of @entity16 values) was calculated. @entity15 @entity1 with increased @entity20698 values showed significantly higher @entity15 Severity Score and magnetic resonance imaging lesion number. The presence of OCMB (P  <  0.0001) and elevated T and B lymphocyte counts was associated with increased levels of CSF @entity20698 . CONCLUSIONS: High CSF @entity20698 levels are associated with elevated CSF lymphocyte cell counts and intrathecal synthesis of IgM against lipids. These findings support a role for OCMB in the @entity21 of @entity15 offering a rationale for the association of these antibodies with disability and @entity1010 in @entity15 .

title: Cerebrospinal fluid immunological biomarkers associated with @entity21 in XXXX .

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['NIND', 'non-inflammatory neurological diseases']

entities_list: @entity1010 :: ('MESH:C566985', 'Disease') :: ['brain atrophy progression']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegeneration']

entities_list: @entity21 :: ('MESH:D001480', 'Disease') :: ['axonal injury', 'axonal damage']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'Multiple Sclerosis']

answer: @entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']


abstract: BACKGROUND: Few studies have addressed the pragmatic management of ambulatory @entity1 with suspected @entity497 ( @entity497 ) using a precise description of the disease with or without chest X-ray (X-ray) evidence. AIMS: To describe the characteristics, clinical findings, additional investigations and disease progression in @entity1 with suspected @entity497 managed by French General Practitioners (GPs). METHODS: The @entity1 included were older than 18 years, with signs or symptoms suggestive of @entity497 associated with recent-onset unilateral crackles on auscultation or a new opacity on X-ray. They were followed for up to 6 weeks. Descriptive analyses of all @entity1 and according to their management with X-rays were carried out. RESULTS: From September 2011 to July 2012, 886 @entity1 have been consulted by 267 GPs. Among them, 278 (31%) were older than 65 years and 337 (38%) were at increased risk for invasive @entity66 . At presentation, the three most common symptoms, cough (94%), @entity221 (93%), and @entity425 or @entity925 (81%), were all observed in 70% of @entity1 . Unilateral crackles were observed in 77% of @entity1 . Among @entity1 with positive radiography (64%), 36% had no unilateral crackles. A null CRB-65 score was obtained in 62% of @entity1 . Most @entity1 (94%) initially received antibiotics and experienced uncomplicated disease progression regardless of their management with X-rays. Finally, 7% of @entity1 were hospitalised and 0.3% died. CONCLUSIONS: Most @entity1 consulting GPs for suspected @entity497 had the three following most common symptoms: cough, @entity221 , and @entity425 or @entity925 . More than a third of them were at increased risk for invasive @entity66 . With or without X-rays, most patients received antibiotics and experienced uncomplicated disease progression.

title: Suspected XXXX in an ambulatory setting (CAPA): a French prospective observational cohort study in general practice.

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['pneumococcal disease']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity497 :: ('MESH:D003147', 'Disease') :: ['CAP', 'community-acquired pneumonia']

answer: @entity497 :: (MESH:D003147,Disease) :: ['community-acquired pneumonia']


abstract: BACKGROUND: Recent data suggest that serum @entity2313 concentrations increase during the several month-period that follows the initiation of @entity22 ( @entity22 ) therapy. Some investigators have shown that the rate of increase in serum @entity2313 level is related directly to 24-hour urine protein losses before the initiation of dialysis therapy. However, serum @entity2313 levels increase even in @entity1 starting @entity22 therapy without significant @entity644 , suggesting that this increase may be one manifestation of improving protein-energy nutritional status associated with commencing @entity22 therapy. We examined this question by reviewing records of all @entity1 admitted to our outpatient dialysis unit within 30 days of initiation of @entity22 therapy. METHODS: Ninety-seven @entity1 qualified for the study. Their routine laboratory test results beginning with the time of admission to the outpatient unit until month 6 of chronic dialysis therapy were analyzed. RESULTS: Between months 1 and 6, there was a statistically significant increase in values for predialysis serum @entity2313 , @entity68 , @entity69 saturation, @entity1011 , and normalized protein equivalent of total @entity1568 appearance (nPNA). Many of these values were still increasing by month 6. Body weight declined initially until month 4, then increased. There was a strong curvilinear relationship between mean nPNA and final serum @entity2313 level. CONCLUSIONS: Our results suggest that an improvement in nutritional status, including an increase in dietary protein intake and serum @entity2313 level, often occurs with the initiation of @entity22 therapy. The improvement in nutritional status may be related to the increase in dietary protein intake.

title: Improvement of nutritional status after initiation of XXXX .

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['maintenance hemodialysis', 'MHD']

answer: @entity22 :: (MESH:D007319,Disease) :: ['maintenance hemodialysis']


abstract: PURPOSE: To assess the benefit and the effect of intraarterial @entity4831 application on histological analysis of @entity1 suspected of having @entity157 . To determine whether @entity4831 marking leads to a better biopsy result and how @entity4831 or a transarterial chemoembolization influences the histological diagnosis. MATERIALS AND METHODS: Two groups of @entity1 were examined. Group A included 14 @entity1 highly suspected of having an @entity157 which had previously been unsuccessfully biopsied. A transarterial embolization with @entity4831 was performed in these @entity1 to mark @entity5 which could not otherwise be defined in unenhanced CT. A biopsy was then repeated. Group B included 22 @entity1 undergoing therapy using transarterial chemoembolization (TACE). A biopsy was performed to support the diagnosis of a multifocal @entity157 before changing the therapy. RESULTS: The transversal diameters of the biopsied @entity5 were similar in both groups (A: 22 mm; B: 21 mm). The length of percutaneous access was 71 mm in Group A and 88 mm in Group B. In eleven of 14 @entity1 of Group A we confirmed the diagnosis of an @entity157 . Thirty-six procedures were necessary for this confirmation. In Group B we confirmed the diagnosis in 17 of 22 @entity1 . In addition, we found typical histological modification due to @entity1575 and @entity1956 . @entity4831 had no negative influence on the histological diagnosis. CONCLUSION: Applying @entity4831 for marking and delineating @entity96 in cases of formerly negative histology seems to enhance the success of biopsy, confirming the diagnosis of an @entity157 .

title: [Prospective benefit and effect of XXXX marking in @entity157 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1956 :: ('MESH:D006509', 'Disease') :: ['virus hepatitis']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['HCC-suspicious liver tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['intrahepatic tumors', 'tumors']

entities_list: @entity4831 :: ('MESH:D004998', 'Chemical') :: ['lipiodol', 'Lipiodol']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['hepatic cirrhosis']

answer: @entity4831 :: (MESH:D004998,Chemical) :: ['lipiodol']


abstract: INTRODUCTION: One of the complications associated with @entity28 is @entity1561 ( @entity1561 ), which is defined as an excessive accumulation of fat in hepatocytes, and is characterized by chronic elevation of aminotransferases and ultrasonographic abnormalities (increased echogenicity). In the USA it is now the most common @entity409 . Prevalence is around 15-25% in the general population, and this increases to 57.5-75% in @entity28 @entity1 . The aim of this study was to evaluate whether @entity1560 is a factor associated with the presence of metabolic risk in @entity1 and @entity28 adolescents. MATERIALS AND METHODS: A retro- and perspective cross-sectional study in the High Specialty Medical Unit No. 25 of the Mexican Social Security Institute in Monterrey, Nuevo Leon, Mexico, in which the clinical records of @entity1 from 5 to 15 years of age, referred with a diagnosis of @entity28 , were reviewed in the period of January 1, 2012 to June 30, 2013. @entity1 and adolescent @entity1 diagnosed with @entity28 were included, but we excluded @entity1 with a history of @entity99 and use of antiepileptic and hepatotoxic drugs. For descriptive analysis we used absolute frequencies, percentages, means, and standard deviations. For inferential analysis we used chi-square test, Fisher exact test, and Student t test to establish the association of @entity1561 with the studied variables. The odds ratio was measured, considering 95% CI and statistical significance p < 0.05. RESULTS: 160 @entity1 and adolescent @entity1 were included with median age 11.23    2.2 years, of which 85 (53.1%) were male and 75 (46.9%) were female. All were @entity28 , with BMI and abdominal circumference greater than the 95th percentile for age. In total, 131 (81.8%) @entity1 had @entity1561 and 29 (18.2 %) @entity1 did not. HOMA index was increased by 3.9    2.1 (p < 0.05) in @entity1 in the @entity1561 group with a mean of 6.4    4.9 in the group without @entity1561 . The cutoff point we found for insulin resistance associated with @entity1561 was 9. We found four subjects with high LDL levels of (> 130), and none in the control group. Transaminase levels were significantly higher in the group of @entity1 with @entity1561 , ALT greater than 40 U/l in 127 (96.94%) of @entity1 with @entity1561 (OR: 63.5; 95% CI: 18.5-217; p < 0.005). LDL-C greater than 130 mg/dl occurred in four (3%) @entity1 with @entity1561 , and in none of the @entity1 without @entity1561 (p = 0.0001). Acanthosis nigricans was found in 128 (97.7%) @entity1 with @entity1561 and in only one (3.4 %) in the group without @entity1561 (OR: 1194.7; 95% CI: 119.8-1191.5; p = 0.0001). CONCLUSION: @entity28 and insulin resistance are risk factors for the development of @entity1560 in @entity1 and adolescents.

title: [ @entity1560 (HS) as a factor associated with the presence of metabolic risk in schoolchildren and XXXX adolescents].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'people']

entities_list: @entity1560 :: ('MESH:D005234', 'Disease') :: ['hepatic steatosis', 'fatty liver']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obese', 'obesity']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity1561 :: ('MESH:D065626', 'Disease') :: ['NAFLD', 'nonalcoholic fatty liver disease']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['acute and chronic viral hepatitis']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obese']